Table 1.
Baseline tumor and patient characteristics
| BRAF | Primary tumor site | |||
|---|---|---|---|---|
| Mutant (N = 12) | Wild type (N = 54) | Left-sided (N = 70) | Right-sided (N = 16) | |
| Median age (range), years | 60 (32–71) | 59.5 (33–76) | 58 (31–77) | 62 (32–72) |
| Sex | ||||
| Male | 6 (50.0%) | 38 (70.4%) | 50 (71.4%) | 9 (56.3%) |
| Female | 6 (50.0%) | 16 (29.6%) | 20 (28.6%) | 7 (43.8%) |
| Treatment arm | ||||
| FOLFOXIRI | 7 (58.3%) | 16 (29.6%) | 22 (31.4%) | 8 (50.0%) |
| mFOLFOXIRI + panitumumab | 5 (41.7%) | 38 (70.4%) | 48 (68.6%) | 8 (50.0%) |
| BRAF mutational status | ||||
| Wild type | 48 (68.6%) | 6 (37.5%) | ||
| Mutant | 6 (8.6%) | 6 (37.5%) | ||
| Unknown | 16 (22.9%) | 4 (25.0%) | ||
| Primary tumor location | ||||
| Left sided | 6 (50.0%) | 43 (79.6%) | ||
| Right sided | 6 (50.0%) | 11 (20.4%) | ||
| ECOG performance status | ||||
| 0 | 6 (50.0%) | 35 (64.8%) | 45 (64.3%) | 8 (50.0%) |
| 1 | 6 (50.0%) | 18 (33.3%) | 23 (32.9%) | 8 (50.0%) |
| 2 | 0 (0.0%) | 1 (1.9%) | 2 (2.9%) | 0 (0.0%) |
| Carcinoembryonic antigen | ||||
| ≤ 50 ng/ml | 7 (58.3%) | 24 (44.4%) | 33 (47.1%) | 8 (50.0%) |
| > 50 ng/ml | 5 (41.7%) | 28 (51.9%) | 35 (50.0%) | 8 (50.0%) |
| Unknown | 0 (0.0%) | 2 (3.7%) | 2 (2.9%) | 0 (0.0%) |
| Lactate dehydrogenase | ||||
| ≤ 250 U/l | 6 (50.0%) | 23 (42.6%) | 31 (44.3%) | 8 (50.0%) |
| > 250 U/l | 6 (50.0%) | 28 (51.9%) | 36 (51.4%) | 8 (50.0%) |
| Unknown | 0 (0.0%) | 3 (5.6%) | 3 (4.3%) | 0 (0.0%) |
| Tumor-related symptoms | ||||
| Yes | 8 (66.7%) | 24 (44.4%) | 32 (45.7%) | 9 (43.8%) |
| No | 4 (33.3%) | 29 (53.7%) | 37 (52.9%) | 7 (56.3%) |
| Unknown | 0 (0.0%) | 1 (1.9%) | 1 (1.4%) | 0 (0.0%) |
| Metastatic sites | ||||
| Liver | 10 (83.3%) | 50 (92.6%) | 65 (92.9%) | 12 (75.0%) |
| Lung | 2 (16.7%) | 13 (24.1%) | 18 (25.7%) | 5 (31.3%) |
| Peritoneum | 4 (33.3%) | 2 (3.7%) | 3 (4.3%) | 4 (25.0%) |
| Distant lymph node/s | 1 (8.3%) | 11 (20.4%) | 15 (21.4%) | 3 (18.8%) |
| Primary surgery | ||||
| Yes | 5 (41.7%) | 27 (50.0) | 34 (48.6%) | 10 (62.5%) |
| No | 6 (50.0%) | 26 (48.1%) | 35 (50.0%) | 5 (31.3%) |
| Unknown | 1 (8.3%) | 1 (1.9%) | 1 (1.4%) | 1 (6.3%) |
| Adjuvant chemotherapy | ||||
| Yes | 0 (0.0%) | 6 (11.1%) | 8 (11.4%) | 0 (0.0%) |
| No | 11 (91.7%) | 47 (87.0%) | 61 (87.1%) | 15 (93.8%) |
| Unknown | 1 (8.3%) | 1 (1.9%) | 1 (1.4%) | 1 (6.3%) |
ECOG performance status according to Eastern Cooperative Oncology Group